Table 1

Patient characteristics

Stage IIIAStage IIIBStage IIICP value
(n=317)(n=18)(n=655)
Mean±SDMean n±SDMean±SD
Age in years59.7±12.160.1±10.860.5±10.10.488
CA125 (IU/mL)109.7±289.9152.6±230.0108±460.90.319
Number of pelvic lymph nodes removed from patients undergoing PLND25.2±12.919.7±10.027.3±13.10.622
Number of para-aortic lymph nodes removed from patients undergoing PALND9.8±9.38.2±5.413.8±10.7<0.0001
n (%)n (%)n (%)P value
Menopausal status0.877
 Pre-53 (16.7)2 (1.1)88 (13.4)
 Post-264 (83.3)16 (8.9)567 (86.6)
Type of surgery0.912
 Laparotomy294 (92.8)17 (94.4)607 (92.7)
 Laparoscopy23 (7.2)1 (5.6)48 (7.3)
Lymphadenectomy<0.001
 None144 (45.4)10 (55.6)0
 Pelvic25 (7.9)3 (16.6)167 (25.5)
 Pelvic+para-aortic148 (46.7)5 (27.8)488 (74.5)
Residual tumor0.811
 0311 (98.2)18 (100)639 (97.5)
 ≤1 cm3 (0.9)010 (1.5)
 >1 cm3 (0.9)06 (0.8)
Grade0.601
 150 (15.8)3 (16.7)115 (17.6)
 2–3267 (84.2)15 (83.3)540 (82.4)
LVSI<0.0001
 Negative106 (33.4)5 (27.8)98 (15)
 Positive168 (53)11 (61.1)529 (80.7)
 Not known43 (13.6)2 (1.1)28 (4.3)
Peritoneal cytology0.002
 Negative148 (46.7)10 (55.6)451 (68.8)
 Positive45 (14.2)2 (1.1)67 (10.2)
 Not performed124 (39.1)6 (33.3)137 (21)
MMI0.023
 09 (2.8)00
 <50%94 (29.7)5 (27.8)150 (22.9)
 ≥50%171 (54)11 (61.1)496 (75.7)
 Not known43 (13.5)2 (1.1)9 (1.4)
Cervical involvement0.211
 No209 (65.9)9 (50)409 (62.4)
 Yes108 (34.1)9 (50)246 (37.6)
Adjuvant treatment modality<0.0001
 None18 (5.7)1 (5.5)5 (0.7)
 RT alone77 (24.3)3 (16.7)99 (15.1)
 CT alone65 (20.5) 157 (49.5)7 (38.9)170 (25.9)
 CRT7 (38.9)381 (58.2)
CT regimen0.01
 Taxol+carboplatin137 (43.1)7 (38.9)340 (51.9)
 Others82 (25.9)7 (38.9)121 (18.4)
 Not known98 (31)4 (22.2)195 (29.7)
Status0.815
 Alive244 (77)13 (72.2)486 (74.2)
 Dead73 (23)5 (27.8)169 (25.8)
  • CRT, chemoradiation; CT, chemotherapy; LVSI, lymphovascular space invasion; MMI, myometrial invasion; PALND, para-aortic lymph node dissection; PLND, pelvic lymph node dissection; RT, radiotherapy.